Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02819232
Other study ID # 2012-40
Secondary ID 2012-A01568-35
Status Completed
Phase N/A
First received
Last updated
Start date August 12, 2013
Est. completion date October 26, 2022

Study information

Verified date April 2023
Source Assistance Publique Hopitaux De Marseille
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infectious keratitis are favored by the circumstances causing the small trauma of the corneal epithelium, corneal surgery, corneal dryness under health system such as Sjögren's syndrome rheumatoid arthritis, or much more frequently wearing contact lenses. If the majority of infectious keratitis are favourable, some lead to serious injury of the cornea, or even corneal perforation which result an endophthalmitis. This unfavourable evolution may lead to blindness due to corneal damage, the endo-ocular lesions or enucleation of the eyeball. This negative evolution is encountered while the infectious keratitis due to tedious germs of difficult diagnosis such as nontuberculous Mycobacterial, fungal infections, fungal keratitis, amoebic keratitis, and certain viral keratitis. The microbiological diagnosis of routine is based on the systematic search for pathogens tedious from invasive sampling of cornea by vaccinostyle. We set up a new non-invasive corneal swab diagnostic method.


Description:

Primary Purpose: Compare the ability diagnostic of non-invasive sampling swab corneal versus the gold standard, (invasive vaccinostyle uptake) for the systematic search for pathogens tedious in corneal specimens. Hypothesis: The diagnostic strategy using a microbial testing of cornea method has a sensitivity of 90% and a specificity of 80% or more over the policy diagnostic using a sampling by vaccinostyle method. Primary outcome measures: Sensitivity, specificity, positive and negative predictive values, Diagnostic odds ratio.


Recruitment information / eligibility

Status Completed
Enrollment 442
Est. completion date October 26, 2022
Est. primary completion date March 6, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient is more than 18 years old. - Patient with a prescription of a microbiologic diagnostic of keratitis - Patient who do not declined to have his medical records reviewed for research - Patient with health insurance Exclusion Criteria: - minor patient (<18 years). - Pregnant or breastfeeding women. - Major Patient under guardianship. - Patient in vital emergency. - Private Patient liberty or under court order. - Patient refusing to sign the informed consent form

Study Design


Intervention

Other:
Blood sampling
Detection of bacteria will be performed on a blood sample

Locations

Country Name City State
France Assistance Publique Hopitaux de Marseille Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity, specificity, positive and negative predictive values, Diagnostic odds ratio. 1 day
See also
  Status Clinical Trial Phase
Completed NCT04030403 - Investigation of the Microbiome of the Cornea in Microbial Keratitis
Completed NCT04213313 - Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis
Recruiting NCT02570321 - Cross-linking for Corneal Ulcers Treatment Trial Phase 4
Terminated NCT00912509 - Cross Linking for Treatment of Corneal Infection N/A
Completed NCT01831206 - Collagen Cross-linking in Infectious Keratitis Trial Phase 2
Completed NCT04383431 - Cross-linking as Treatment in Infectious Keratitis N/A
Recruiting NCT05888987 - Use of a New Method for the Microbiological Diagnosis of Severe Corneal Infection
Not yet recruiting NCT03801590 - Crosslinking in Infectious Keratitis N/A
Recruiting NCT06364878 - Non-invasive Diagnostics of Microbial Keratitis
Completed NCT01739673 - Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis N/A